

Dear colleagues,

as decided in the recent ILTE Steering Committee meeting, a protocol has been prepared to validate a new assay that could help us in the future to identify a priori those patients that will be able to stop imatinib treatment without experiencing relapses.

This draft must be considered for what it is: a draft, open to modifications.

After discussion with several IRBs, I reached the conclusion that an amendment to ILTE was not the right tool, but that a new protocol was indeed necessary.

Here below you will find the draft of such a protocol. Although this protocol is not restricted to ILTE participants, I think appropriate to propose it first to ILTE study members, since the data accumulated in the past years (thanks to your cooperation) will greatly facilitate the proposed study.

I ask that you reply to me by *****September 10rd*****, indicating if you wish to participate in this protocol, and how many patients you plan to enroll.

I will also appreciate any comment and suggestion on the enclosed draft.

I look forward to hearing from you soon.

With best regards.
Sincerely,

--

Carlo Gambacorti-Passerini MD
ILTE Study Chairman
University of Milano Bicocca
S.Gerardo Hospital
Via Cadore 48
20052 Monza - Italy

tel +39.039.233-9553/-3539
fax +39.039.233-3539

E-mail carlo.gambacorti@unimib.it
http://www.dimep.medicina.unimib.it/en/staff_174.php?docente_id=32

Please click on the link below to open the draft of the protocol:
http://www.ilte-cml.org/10_protocol.pdf